Nutra Pharma Corp.
Bringing Healthcare Solutions to the World
 
Newsroom
Recent News
Archives
E-Alerts
Drug Development
R&D Pipeline
Nutra Pharma is developing an innovative pipeline of biopharmaceutical products
E-Alerts
Signup to receive news and announcements from Nutra Pharma:
First Name:
Last Name:
Email:
Infinite Menus, Copyright 2006, OpenCube Inc. All Rights Reserved.

Newsroom

Nutra Pharma Announces Shareholder Conference Call Scheduled for Wednesday, February 14, 2007
February 14, 2007

Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that it has scheduled a shareholder conference call for today at 4:00PM EST to further explain the Company’s recent news and continued progress. The call will feature a presentation by Rik J. Deitsch, Chairman and CEO of Nutra Pharma, along with presentations by Stewart Lonky, MD, a Director of the Company, and Neil Roth, President of Designer Diagnostics. The presentations will be followed by a 15 minute question and answer session.

“The Company has been moving forward quickly as is clearly evidenced from all of our recent press releases,” commented Mr. Deitsch. “We would like to invite all of our shareholders and other interested parties to join us on this conference call so that we may explain our progress and the short-term and mid-term implications of these accomplishments,” he added.

For details on the call as well as dial-in information, please visit the Nutra Pharma website at: http://www.NutraPharma.com.

SEC Disclaimer

This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The shareholder conference call scheduled for February 14, 2007 should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.


 
Quick Nav
Cobroxin for Chronic Pain
Nyloxin // Chronic Pain Relief

 

 
Recent News
 
August 19, 2010
Nutra Pharma Begins Drug Registration Process in India for Nyloxin - a Treatment for Moderate to Severe Chronic Pain


August 09, 2010
Nutra Pharma Announces Amarey Nova Medical as its Exclusive Nyloxin Distributor in Colombia


August 06, 2010
Nutra Pharma Announces Second Quarter 2010 Sales and Distribution Update


 
 
Announcements
Click here to learn more about Nyloxin, our over-the-counter treatment for moderate to severe chronic pain.
 
 
Facebook   Twitter
 
NPC
Privacy Policy Code of Ethics